Publication Name	World Journal of Transplantation
Manuscript ID	120572
Country	United Kingdom

Category	Transplantation
Manuscript Type	Minireviews
Article Title	Redefining weight management after liver transplantation with glucagon-like peptide one and gastric inhibitory polypeptide receptor agonists
Manuscript Source	Invited Manuscript
All Author List	Soha Elatrebi, Rowan Abuyadek, Sohaila Mohamed Mohamed Abdelbar, Muhammad S Ahmad, Mohamed Ayyad, Muhammad AbdelAziz Quoritem, Rodaina Osama Abdel Majid, Manar Arafat, Ahmed Amgad and Amr Alnagar
Funding Agency and Grant Number
Corresponding Author	Amr Alnagar, PhD, Department of General Surgery, University Hospitals of Birmingham, 6 Chamberlain Road, Birmingham B9 5SS, United Kingdom. amr.alnagar@nhs.net
Key Words	Liver transplantation; Obesity; Metabolic syndrome; Steatosis; Weight loss
Core Tip	While liver transplantation can be life-saving for end-stage liver diseases, it can exacerbate metabolic issues due to underlying pathology and immunosuppressive regimens. A thorough management plan is essential to prevent complications like metabolic dysfunction-associated steatotic liver disease, chronic renal dysfunction, and diabetes, ultimately improving prognosis and quality of life. glucagon-like peptide-1 (GLP-1) and GLP-1/glucose-dependent insulinotropic polypeptide receptor agonists have gained United States Food and Drug Administration approval for long-term weight management, but their long-term safety, optimal dosing, and effectiveness in transplant recipients remain underexplored. This review addresses the pathophysiology, risk factors, and burden of metabolic complications in liver transplant recipients while evaluating the potential role of GLP-1 and GLP-1/glucose-dependent insulinotropic polypeptide receptor agonists for managing these issues.
Citation	Elatrebi S, Abuyadek R, Abdelbar SMM, Ahmad MS, Ayyad M, Quoritem MA, Abdel Majid RO, Arafat M, Amgad A, Alnagar A. Redefining weight management after liver transplantation with glucagon-like peptide one and gastric inhibitory polypeptide receptor agonists. World J Transplant 2026; In press

Received	2026-03-02 03:33
Peer-Review Started	2026-03-02 03:34
First Decision by Editorial Office Director	2026-03-04 08:59
Return for Revision	2026-03-04 08:59
Revised	2026-03-18 07:00
Publication Fee Transferred
Second Decision by Editor	2026-05-19 02:43
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2026-05-19 11:42
Articles in Press	2026-05-19 11:42
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	2220-3230 (online)
Open Access	This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Copyright	©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com